The Swiss drug development company Windward Bio recently announced that it had officially launched with a $200 million Series ...
The US gene therapy company Regenxbio and the Japanese firm Nippon Shinyaku have joined forces to boost the development and commercialization of Regenxbio’s gene therapies RGX-121 for the treatment of ...
MaaT Pharma is focused on developing microbiome-related therapies and its lead candidate is MaaT013, a treatment for acute ...
The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.
The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, ...
Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...
Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback